Cai C, Chen JM, Qiu ZX, Ren SQ. Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies. World J Clin Oncol 2026; 17(2): 116390 [PMID: 41810339 DOI: 10.5306/wjco.v17.i2.116390]
Corresponding Author of This Article
Shu-Qi Ren, Associate Research Scientist, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, No. 10 Dexiu Road, Zhongshan 528467, Guangdong Province, China. shuchijen@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cai C, Chen JM, Qiu ZX, Ren SQ. Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies. World J Clin Oncol 2026; 17(2): 116390 [PMID: 41810339 DOI: 10.5306/wjco.v17.i2.116390]
World J Clin Oncol. Feb 24, 2026; 17(2): 116390 Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.116390
Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies
Chuang Cai, Jin-Man Chen, Zu-Xun Qiu, Shu-Qi Ren
Chuang Cai, Department of Cancer Research Institute of Zhongshan, Zhongshan People’s Hospital, Zhongshan 528445, Guangdong Province, China
Jin-Man Chen, Department of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China
Zu-Xun Qiu, Shu-Qi Ren, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, Zhongshan 528467, Guangdong Province, China
Co-first authors: Chuang Cai and Jin-Man Chen.
Author contributions: Cai C and Chen JM contributed to the work equally and are co-first authors of this manuscript; Cai C and Chen JM conceived the review and drafted the initial manuscript; Cai C, Chen JM, Qiu ZX, and Ren SQ made substantial contributions to this manuscript; Chen JM and Qiu ZX were responsible for literature collation; Cai C and Ren SQ edited and finalized the manuscript for submission; and all authors reviewed and approved the submitted manuscript.
Supported by Zhongshan Science and Technology Bureau, No. 2023B1033.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shu-Qi Ren, Associate Research Scientist, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, No. 10 Dexiu Road, Zhongshan 528467, Guangdong Province, China. shuchijen@163.com
Received: November 11, 2025 Revised: December 1, 2025 Accepted: December 24, 2025 Published online: February 24, 2026 Processing time: 87 Days and 24 Hours
Abstract
This commentary discusses the groundbreaking study by Ebrahim et al on the role of claudin-6 (CLDN6) in high-grade endometrial carcinoma, addressing a significant gap in current knowledge. Their research reveals that overexpression of CLDN6 is linked to unfavorable pathological features. Moreover, multivariate analysis establishes CLDN6 as an independent predictor of disease-free survival, with a hazard ratio of 68.98. These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.
Core Tip: This editorial focuses on the expression and clinical importance of the tight junction protein claudin-6 (CLDN6) in high-grade endometrial carcinoma. It demonstrates that CLDN6 overexpression independently correlates with aggressive pathological characteristics and poor patient outcomes. These findings underscore CLDN6’s value as a prognostic biomarker and highlight its potential as a therapeutic target, opening new possibilities for improved risk stratification and personalized treatment strategies in high-grade endometrial carcinoma.
